| DB ID | MyCo_1723 |
| Title | Modulation of the systemic inflammatory response by recombinant human interleukin-11: a prospective randomized placebo controlled clinical study in patients with hematological malignancy |
| Year | 2006 |
| PMID | 16644288 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | Hematological malignancy |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | rhIL-11 |
| Biomarker Full Name | Recombinant human interleukin-11 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UAE |
| Cohort | Persons with a diagnosis of acute myeloid or lymphoblastic leukemia or non-Hodgkin’s lymphoma were admitted to the Haematology Ward of Tawam Hospital. A total of 898 daily serum samples (466 placebo group, 432 rhIL-11 group) were collected for cytokine analysis, representing a mean observation period of 24 days on placebo treatment and 21.5 days on rhIL-11 treatment. |
| Cohort No. | 898 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | human ELISA kits: sTNFRI DuoSet ELISA kit [Cat #DY225] from R&D systems (Minneapolis, MN, USA) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
